Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel.
Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel.
复制标题
DOI:
10.3389/fmed.2021.836658
复制
发表时间:
2021
影响因子:
3.9
通讯作者:
Bishop-Lilly KA
中科院分区:
文献类型:
--
作者:
Smith DR;Singh C;Green J;Lueder MR;Arnold CE;Voegtly LJ;Long KA;Rice GK;Luquette AE;Miner HL;Glang L;Bennett AJ;Miller RH;Malagon F;Cer RZ;Bishop-Lilly KA
The emergence of SARS-CoV-2 variants complicates efforts to control the COVID-19 pandemic. Increasing genomic surveillance of SARS-CoV-2 is imperative for early detection of emerging variants, to trace the movement of variants, and to monitor effectiveness of countermeasures. Additionally, determining the amount of viable virus present in clinical samples is helpful to better understand the impact these variants have on viral shedding. In this study, we analyzed nasal swab samples collected between March 2020 and early November 2021 from a cohort of United States (U.S.) military personnel and healthcare system beneficiaries stationed worldwide as a part of the Defense Health Agency's (DHA) Global Emerging Infections Surveillance (GEIS) program. SARS-CoV-2 quantitative real time reverse-transcription PCR (qRT-PCR) positive samples were characterized by next-generation sequencing and a subset was analyzed for isolation and quantification of viable virus. Not surprisingly, we found that the Delta variant is the predominant strain circulating among U.S. military personnel beginning in July 2021 and primarily represents cases of vaccine breakthrough infections (VBIs). Among VBIs, we found a 50-fold increase in viable virus in nasal swab samples from Delta variant cases when compared to cases involving other variants. Notably, we found a 40-fold increase in viable virus in nasal swab samples from VBIs involving Delta as compared to unvaccinated personnel infected with other variants prior to the availability of approved vaccines. This study provides important insight about the genomic and virological characterization of SARS-CoV-2 isolates from a unique study population with a global presence.
登录
查看更多内容
DOI:
10.1016/s1473-3099(21)00475-8
发表时间:
2022-01
期刊:
The Lancet. Infectious diseases
影响因子:
--
作者:
Twohig KA;Nyberg T;Zaidi A;Thelwall S;Sinnathamby MA;Aliabadi S;Seaman SR;Harris RJ;Hope R;Lopez-Bernal J;Gallagher E;Charlett A;De Angelis D;Presanis AM;Dabrera G;COVID-19 Genomics UK (COG-UK) consortium
通讯作者:
COVID-19 Genomics UK (COG-UK) consortium
DOI:
10.1126/science.abg3055
发表时间:
2021-04-09
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者:
Edmunds WJ
影响因子:
16.6
作者:
Li B;Deng A;Li K;Hu Y;Li Z;Shi Y;Xiong Q;Liu Z;Guo Q;Zou L;Zhang H;Zhang M;Ouyang F;Su J;Su W;Xu J;Lin H;Sun J;Peng J;Jiang H;Zhou P;Hu T;Luo M;Zhang Y;Zheng H;Xiao J;Liu T;Tan M;Che R;Zeng H;Zheng Z;Huang Y;Yu J;Yi L;Wu J;Chen J;Zhong H;Deng X;Kang M;Pybus OG;Hall M;Lythgoe KA;Li Y;Yuan J;He J;Lu J
通讯作者:
Lu J
DOI:
10.1093/cid/ciab986
发表时间:
2022-08-24
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
作者:
Huai Luo C;Paul Morris C;Sachithanandham J;Amadi A;Gaston DC;Li M;Swanson NJ;Schwartz M;Klein EY;Pekosz A;Mostafa HH
通讯作者:
Mostafa HH
影响因子:
3.7
作者:
Bushnell B;Rood J;Singer E
通讯作者:
Singer E